Clinical trial · Observational
HER2-positive Breast Cancer Registry
Prospective Evaluation of Outcomes for HER2-positive Breast Cancer (PRO-HER2)
NCT06603597CI-TRIAL-00118415PRO-HER2recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this observational study is to better understand links between patient or tumor characteristics and outcomes in HER2-positive breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| HER2 + Breast Cancer | Breast Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- HER2-positive breast cancer
- description
- Patients with stage I-IV HER2-positive breast cancer
Primary outcomes (1)
- measure
- Overall survival rate
- timeFrame
- From diagnosis to 5 years after diagnosis
- description
- For patients with stage I-III HER2-positive breast cancer, percentage of patients who are alive at 5 years after diagnosis.
Secondary outcomes (1)
- measure
- Pathologic complete response rate
- timeFrame
- From start of neoadjuvant systemic treatment until approximately 8 months after start of neoadjuvant systemic treatment
- description
- Percentage of patients with stage I-III HER2-positive breast cancer who received neoadjuvant systemic therapy and experienced pathologic complete response.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Stage I-IV HER2-positive breast cancer Exclusion Criteria: * None
References
Publications (0)
Data not yet available
No reference posted for this study.